Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients

• Published in: Journal of neuroimmunology Vol. 303; pp. 75 - 80
• Main Authors: Paolicelli, D, Manni, A, D ' Onghia, M, Direnzo, V, Iaffaldano, P, Zoccolella, S, Di Lecce, V, Tortorella, C, Specchia, G, Trojano, M
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.02.2017
• Subjects: Adult; Allergy and Immunology; Biomarkers - blood; Cohort Studies; Female; Fingolimod; Fingolimod Hydrochloride - pharmacology; Fingolimod Hydrochloride - therapeutic use; Follow-Up Studies; Humans; Immune system re-modulation; Immunosuppressive Agents - pharmacology; Immunosuppressive Agents - therapeutic use; Lymphocyte subsets; Lymphocyte Subsets - drug effects; Lymphocyte Subsets - immunology; Lymphocyte Subsets - metabolism; Lymphocytes; Male; Middle Aged; Multiple Sclerosis biomarkers; Multiple Sclerosis, Relapsing-Remitting - blood; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - immunology; Neurology; Treatment Outcome; L ymphocytes; Fingolimod; Multiple Sclerosis biomarkers; Lymphocyte sub s ets; I mmune system re-modulation; Immune system re-modulation; Lymphocyte subsets; Lymphocytes
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/j.jneuroim.2016.12.012

Abstract We investigated, lymphocyte count (LC) and lymphocyte subsets (LS ) in a real life setting of Fingolimod (FTY) treated Relapsing MS (RMS) patients . Peripheral blood counts with LS, relapses and MRI scans were recorded in a cohort of 119 FTY patients, during one year of treatment. Simple and multivariate logistic regression models, were performed. ROC analysis identified cut-off values of LS predicting a higher risk of relapses and of Gd + lesions. We demonstrated a FTY-induced re-modulation of the immune system, suggesting that LS in RMS FTY treated patients can predict the clinical response to the drug.